Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.

[1]  E. Kobayashi,et al.  In vivo bioimaging using photogenic rats: fate of injected bone marrow-derived mesenchymal stromal cells. , 2008, Journal of autoimmunity.

[2]  A. Marmont.  Will hematopoietic stem cell transplantation cure human autoimmune diseases? , 2008, Journal of autoimmunity.

[3]  Y. Sonoda.  Immunophenotype and functional characteristics of human primitive CD34-negative hematopoietic stem cells: the significance of the intra-bone marrow injection. , 2008, Journal of autoimmunity.

[4]  M. Gershwin,et al.  On reversing the persistence of memory: hematopoietic stem cell transplant for autoimmune disease in the first ten years. , 2008, Journal of autoimmunity.

[5]  M. Gershwin.  Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara. , 2008, Journal of autoimmunity.

[6]  Kazuya Sato,et al.  Cell and gene therapy using mesenchymal stem cells (MSCs). , 2008, Journal of autoimmunity.

[7]  A. Testori,et al.  Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned? , 2008, Journal of autoimmunity.

[8]  N. Abraham,et al.  Bone marrow stem cell transplant into intra-bone cavity prevents type 2 diabetes: role of heme oxygenase-adiponectin. , 2008, Journal of autoimmunity.

[9]  M. Ratajczak,et al.  Hunt for pluripotent stem cell -- regenerative medicine search for almighty cell. , 2008, Journal of autoimmunity.

[10]  M. Gershwin,et al.  The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. , 2008, Journal of autoimmunity.

[11]  A. Fefer.  Graft‐Vs.‐Tumor Responses , 2007 .

[12]  H. Heslop,et al.  Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. , 2007, Blood.

[13]  F. Appelbaum,et al.  Hematopoietic-cell transplantation at 50. , 2007, The New England journal of medicine.

[14]  D. Cornfield,et al.  The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. , 2007, Blood.

[15]  F. Appelbaum,et al.  Graft-Versus-Host Disease: A Surge of Developments , 2007, PLoS medicine.

[16]  L. Hambach,et al.  Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. , 2007, Best practice & research. Clinical haematology.

[17]  A. Tyndall,et al.  Autoimmunity following haematopoietic stem-cell transplantation. , 2007, Best practice & research. Clinical haematology.

[18]  S. Ikehara.  Innovative BMT methods for intractable diseases , 2007, Immunologic research.

[19]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[20]  C. Min,et al.  IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation , 2007, Bone Marrow Transplantation.

[21]  J. P. McCoy,et al.  Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. , 2007, Blood.

[22]  W. Murphy,et al.  Immunobiology of allogeneic hematopoietic stem cell transplantation. , 2007, Annual review of immunology.

[23]  M. Martelli,et al.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. , 2006, Blood.

[24]  D. Valmori,et al.  Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells1 , 2006, The Journal of Immunology.

[25]  W. Selby,et al.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.

[26]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[27]  E. Zorn.  CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. , 2006, Seminars in cancer biology.

[28]  E. Warren,et al.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. , 2006, Blood.

[29]  D. Fowler.  Shared biology of GVHD and GVT effects: potential methods of separation. , 2006, Critical reviews in oncology/hematology.

[30]  Alexander Perl,et al.  A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. , 2006, Blood.

[31]  P. Hari,et al.  NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. , 2006, Blood.

[32]  A. Attarbaschi,et al.  Expression of the putatively regulatory T-cell marker FOXP3 by CD4(+)CD25+ T cells after pediatric hematopoietic stem cell transplantation. , 2006, Haematologica.

[33]  E. Warren,et al.  Adoptive transfer of allogeneic antigen-specific T cells. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  R. Storb,et al.  Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  Jeffrey S. Miller,et al.  KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. , 2005, Blood.

[36]  T. Sayers,et al.  Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. , 2005, Blood.

[37]  Craig W. Reynolds,et al.  Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma , 2005, Bone Marrow Transplantation.

[38]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[39]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[40]  室井 一男.  What's going on 造血器腫瘍 1)Human mesenchymal stem cells modulate allogeneic immune cell responses. Aggarwal S, Pittenger MF. Blood. 2005;105:1815-22. PMID:15494428. 2)Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Le Blanc K, Rasmusson I, Sun , 2005 .

[41]  M. Heemskerk,et al.  Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. , 2005, Haematologica.

[42]  D. Neuberg,et al.  CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study , 2004, Bone Marrow Transplantation.

[43]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[44]  C. Dinarello,et al.  Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Barrett,et al.  Review Articles (434 articles) , 2003 .

[46]  F. Appelbaum,et al.  Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. , 2004, Blood.

[47]  F. Appelbaum,et al.  Thomas' hematopoietic cell transplantation , 2003 .

[48]  E. Warren,et al.  The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. , 2003, Blood reviews.

[49]  Els Goulmy,et al.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[51]  J. Goldman,et al.  Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. , 2002, Blood.

[52]  N. Schmitz,et al.  Is there a graft‐versus‐leukaemia effect in the absence of graft‐versus‐host disease in patients undergoing bone marrow transplantation for acute leukaemia? , 2000, British journal of haematology.

[53]  J. Dick,et al.  CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Verdijk,et al.  Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. , 1999, Blood.

[55]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  A. Bakker,et al.  Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. , 1992, Journal of immunology.

[57]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[58]  J. Loutit,et al.  Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II , 1957, British journal of haematology.

[59]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.